tRNA-Arg-TCT-4-1を標的とすることで、がん細胞の増殖と腫瘍形成を抑制する

科学分野:

• Molecular Biology
• Cancer Research
• Genetics

背景:

• Transfer RNAs (tRNAs) are crucial for protein synthesis and can influence cancer progression.
• The specific role of endogenous tRNA-Arg-TCT isodecoders in cancer remains largely unexplored.
• tRNA-Arg-TCT-4-1 is a potential oncogenic driver whose necessity in cancer has not been established.

研究 の 目的:

• To investigate the role of the tRNA-Arg-TCT-4-1 isodecoder in human cancers.
• To determine if inhibiting tRNA-Arg-TCT-4-1 can suppress cancer cell growth and tumor progression.
• To explore the therapeutic potential of targeting tRNA-Arg-TCT-4-1 in cancer treatment.

主な方法:

• Analysis of tRNA-Arg-TCT-4-1 expression levels in patient data across various cancer types.
• Utilizing antisense RNA strategies to specifically inhibit tRNA-Arg-TCT-4-1 in glioblastoma (GBM) and liposarcoma (LPS) cell lines.
• Investigating the impact of tRNA-Arg-TCT-4-1 inhibition on mRNA translation and proteome remodeling.
• Conducting intratumoral delivery of an antisense oligonucleotide (ASO) targeting tRNA-Arg-TCT-4-1 in mouse xenograft models.

主要な成果:

• Elevated tRNA-Arg-TCT-4-1 levels are associated with poor patient prognosis in multiple cancers.
• Specific inhibition of tRNA-Arg-TCT-4-1 suppressed the growth of GBM and LPS cancer cells.
• tRNA-Arg-TCT-4-1 inhibition induced codon-biased translation changes, reducing expression of growth-promoting genes.
• Intratumoral ASO delivery targeting tRNA-Arg-TCT-4-1 suppressed tumor growth and extended survival in preclinical models.

結論:

• tRNA-Arg-TCT-4-1 is a critical driver in certain cancers and a potential therapeutic target.
• Antisense oligonucleotide (ASO)-mediated inhibition of tRNA-Arg-TCT-4-1 shows promise for cancer therapy.
• Targeting tRNA dysregulation represents a novel strategy for cancer treatment.